ReviewJournal of translational medicine2025
Epigenetic modifier m⁶A methylation: insights into the pathogenesis and therapeutic potential of autoimmune diseases.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The gut-joint axis in gout: microbial outer membrane vesicles and mFrontiers in immunology · 2026Review
- Immune signaling as a determinant of cellular identity and tissue function.Frontiers in immunology · 2026Review
- Decoding autoimmune disease with single-cell immune repertoire and transcriptome sequencing: mechanisms and therapeutic opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
N6-methyladenosine (m⁶A) methylation is a predominant form of RNA modification in eukaryotic cells. It exerts profound influence over the processing of mRNA, rRNA and tRNA, thereby playing a critical role in various biological processes, including RNA transcription, splicing, degradation, and translation regulation. The m⁶A methylation significantly affects cell fate and signal transduction pathways by regulating gene expression. Notably, aberrant m⁶A modification is strongly associated with the onset and progression of autoimmune diseases. Emerging evidence indicates that these regulatory factors display disease-specific expression patterns and functional roles, influencing immune-cell differentiation and effector functions, inflammatory responses, and tissue injury. This article provides an overview of recent advances in m⁶A biology in autoimmunity and discusses their implications for diagnosis and therapeutic intervention.Clinical trial number Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.